PI3Kα-IN-4

PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα , with an IC 50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity In Vitro PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC 50 s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays. PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC 50 s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit tumor growth by 73.0% in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily for 30 d) dose dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg) and 90.7% (40 mg/kg), respectively in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily; 1-4 h) inhibits the phosphorylation of Akt in a dose- and time-dependent manner in vivo . PI3Kα-IN-4 shows high C max (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) following oral administration (mouse 10, rat 3 mg/kg) . PI3Kα-IN-4 shows t 1/2 (mouse 0.99, rat 1.22 h) and low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg) following intravenous injection (mouse 1, rat 1 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BT-474 subcutaneous xenograft mice Dosage: 30 mg/kg Administration: P.o. once daily for 21 days Result: Inhibited tumor growth by 73.0% and could be tolerated. IC50& Target:PI3Kα 1.8 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet